India’s cheap weight-loss jabs set global shift

Generic semaglutide rollout could slash prices, widen access across developing world

3m read
By the end of 2026, core patents on semaglutide will have expired in 10 countries that represent 48 percent of the global obesity burden.

LOAD MORE

TRENDING STORIES